FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

Phase 3 Completed 40 enrolled Texas Diabetes & Endocrinology, P.A.

RandomizedCrossoverOpen-labelTreatment

Summary

This is an exploratory, single-center, randomized, open label, active-controlled, complete cross-over trial comparing safety and efficacy of Fiasp® versus NovoLog® when used in the Medtronic MiniMed 670G system in subjects with T1DM.

Timeline

Start: 2019-06-11
Primary completion: 2020-03-09
Completion: 2020-04-20

Outcome

Met primary endpoint

paper The increment in the 1 h postmeal test glucose was significantly lower with FA versus IAsp. PMID 33090016 ↗

Publications

Ozer K, Cooper AM, Ahn LP, Waggonner CR, Blevins TC. Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study. Diabetes Technol Ther. 2021 Apr;23(4):286-292. doi: 10.1089/dia.2020.0500. Epub 2021 Mar 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fast-acting insulin aspart	Protein / enzyme biologic	—	Subcutaneous
Subject	insulin aspart	Protein / enzyme biologic	—	Subcutaneous